Lb Pharmaceuticals (LBRX) Cash & Equivalents (2024 - 2026)

Lb Pharmaceuticals' Cash & Equivalents history runs 3 years deep, the most recent figure standing at $320.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents changed N/A year-over-year to $320.7 million in Q1 2026; TTM through Mar 2026 was $320.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $250.2 million, up 988.75% from the prior year.
• Cash & Equivalents rose to $320.7 million in Q1 2026 per LBRX's latest filing, from $250.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $320.7 million in Q1 2026 and bottomed at $23.0 million in Q4 2024.
• The 3-year median for Cash & Equivalents is $260.0 million (2025), against an average of $215.9 million.
• Biggest YoY gain for Cash & Equivalents was 988.75% in 2025; the steepest drop was 988.75% in 2025.
• Year by year, Cash & Equivalents stood at $23.0 million in 2024, then jumped by 988.75% to $250.2 million in 2025, then rose by 28.18% to $320.7 million in 2026.
• Per Business Quant, the three latest LBRX Cash & Equivalents figures stand at $320.7 million (Q1 2026), $250.2 million (Q4 2025), and $269.7 million (Q3 2025).